Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$25.2 million.

  • Arcutis Biotherapeutics' Cash from Investing Activities fell 12978.05% to -$25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year increase of 15686.0%. This contributed to the annual value of $28.8 million for FY2024, which is 8400.95% down from last year.
  • Arcutis Biotherapeutics' Cash from Investing Activities amounted to -$25.2 million in Q3 2025, which was down 12978.05% from $17.4 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Cash from Investing Activities' 5-year high stood at $107.8 million during Q1 2023, with a 5-year trough of -$197.3 million in Q3 2022.
  • For the 5-year period, Arcutis Biotherapeutics' Cash from Investing Activities averaged around $2.6 million, with its median value being $17.4 million (2025).
  • In the last 5 years, Arcutis Biotherapeutics' Cash from Investing Activities tumbled by 578314.61% in 2022 and then soared by 60439.3% in 2023.
  • Arcutis Biotherapeutics' Cash from Investing Activities (Quarter) stood at $23.5 million in 2021, then soared by 79.59% to $42.2 million in 2022, then crashed by 247.36% to -$62.2 million in 2023, then skyrocketed by 156.08% to $34.9 million in 2024, then plummeted by 172.39% to -$25.2 million in 2025.
  • Its Cash from Investing Activities stands at -$25.2 million for Q3 2025, versus $17.4 million for Q2 2025 and $11.8 million for Q1 2025.